Denali Therapeutics (DNLI) Non-Current Deffered Revenue (2018 - 2022)
Denali Therapeutics (DNLI) posted quarterly Non-Current Deffered Revenue of $479000.0 for Q4 2022, down 85.9% year-over-year from $3.4 million in Q4 2021, and down 85.9% quarter-over-quarter from $3.4 million in Q2 2022.
Denali Therapeutics (DNLI) Non-Current Deffered Revenue (2018 - 2022) Analysis & Trends
Denali Therapeutics (DNLI) has reported Non-Current Deffered Revenue for 5 consecutive years, with $479000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Non-Current Deffered Revenue fell 85.9% year-over-year to $479000.0; the TTM figure through Dec 2022 stood at $479000.0 (down 85.9% YoY), while the FY2022 annual figure was $479000.0, down 85.9% from the prior year.
- Non-Current Deffered Revenue fell to $479000.0 in Q4 2022 per DNLI's latest filing, from $3.4 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $51.5 million in Q1 2018 and bottomed at $479000.0 in Q4 2022.
- Historically, Non-Current Deffered Revenue has averaged $24.4 million across 5 years, with a median of $24.5 million in 2018.
- Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue jumped 4230.71% — and 2022, when it sank 89.15%.
- Denali Therapeutics' Non-Current Deffered Revenue stood at $24.5 million in 2018, then jumped by 78.35% to $43.8 million in 2019, then tumbled by 46.69% to $23.3 million in 2020, then tumbled by 85.43% to $3.4 million in 2021, then plunged by 85.9% to $479000.0 in 2022.
- Business Quant data shows DNLI's Non-Current Deffered Revenue at $479000.0 in Q4 2022, $3.4 million in Q2 2022, and $3.4 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 479,000.00 |
| Jun 30, 2022 | 3.40 Mn |
| Mar 31, 2022 | 3.40 Mn |
| Dec 31, 2021 | 3.40 Mn |
| Sep 30, 2021 | 31.31 Mn |
| Jun 30, 2021 | 31.31 Mn |
| Mar 31, 2021 | 31.32 Mn |
| Dec 31, 2020 | 23.33 Mn |
| Sep 30, 2020 | 16.56 Mn |
| Jun 30, 2020 | 19.72 Mn |
| Mar 31, 2020 | 34.75 Mn |
| Dec 31, 2019 | 43.75 Mn |
| Sep 30, 2019 | 47.80 Mn |
| Jun 30, 2019 | 44.56 Mn |
| Mar 31, 2019 | 44.85 Mn |
| Dec 31, 2018 | 24.53 Mn |
| Sep 30, 2018 | 7.10 Mn |
| Jun 30, 2018 | 1.03 Mn |
| Mar 31, 2018 | 51.52 Mn |